Current Prospective of NLCs in Parkinson’s Disease: An Outlook

Abstract

Parkinson's disease (PD) is 2nd most a neuro-degenerative disorder of the central nervous system affecting 7–10 million people of worldwide as the report of WHO 2014. It occurs due to the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. It is characterized by tremor, rigidity, bradykinesia, dementia, depression and falls or emerges with the progression of the disease. Ropinirole Hydrochloride is a drug of choice which is having low molecular weight, high solubility. It is rapidly absorbed from the gastro intestinal tract and mean peak plasma concentrations have been achieved within 1.5 h after oral doses. The oral bioavailability of Ropinirole HCl is 50% due to extensive first pass metabolism by the liver. Its mean plasma half-life is 5–6hr. The present review work tries to enlighten the prior art related to Parkinson's disease treatment with Ropinirole HCl loaded nanostructured lipid carriers (NLCs) that may overcome the problem of bioavailability and bypass the blood brain barrier and targeted to the brain thereby decreasing the dosing frequency and increasing patient compliance. The promising results of NLC of Ropinirole formulation suggested in this review work provides a futuristic approach for achieving better therapeutic efficacy by being able to target CNS.

Keywords: Bioavailability, Parkinson's disease, nanostructured lipid carriers (NLCs), Nano-technology

Cite this Article

Manoj Kumar Katual, Gurfateh Singh, S.L. Harikumar. Current Prospective of NLCs in Parkinson’s Disease: An Outlook. Research & Reviews: A Journal of Drug Design & Discovery. 2018; 5(2): 18–29p.